Rovadicitinib not checked

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · TQ05105

FollowEvery change as it happens, and a Monday email
Next date
Phase 1/2 trial completes
Trials
8 active
17 in total
Targets
JAK1 · JAK2 · ROCK1 · ROCK2
 

What this is

How it works
Blocks JAK enzymes that pass on immune signals, to calm an overactive immune system.-citinib: Janus kinase inhibitors WHO name stem
How it’s given
“Rovadicitinib is an inhibitor of Janus associated kinases (JAK) family and Rho associated kinases (ROCK). It can inhibit the sustained abnormal activation of the Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway and also inhibit Rho associated kinase 2 (ROCK2). The JAK 1-JAK 2 signaling pathway is a key step in causing inflammation and tissue damage in acute…”In the company’s words, NCT06682169 on ClinicalTrials.gov
Tested for
Myelofibrosis (5 trials), Chronic Graft Versus Host Disease (2 trials), Graft-versus-host Disease
Main trialPhase 3
“The aim of this study is to demonstrate that in subjects with moderate to severe chronic graft-versus-host disease in the third line and beyond, the use of rosuvastatin compared to the protocol chosen by the researchers can significantly improve the objective response rate of subjects at week 24.”In the company’s words, NCT06682169 on ClinicalTrials.gov
Other names
TQ05105

Other drugs for Myelofibrosis

All 37 drugs for Myelofibrosis

Coming up6

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials17

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Oct 2029 Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
Phase 2Recruiting Nov 2027 A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease
Phase 2Recruiting Jun 2028 A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis
Phase 1/2Active, not recruiting 30 Jun 2023 A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease
Phase 1/2Recruiting Dec 2026 A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)
Phase 1Recruiting Oct 2026 To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects
Phase 1Active, not recruiting Dec 2026 Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets
Phase 1Active, not recruiting Dec 2026 QT Interval/Corrected QT Interval (QT/QTc) Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants
Phase 2Completed 15 Oct 2023 A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis
Phase 1/2Terminated 10 Jul 2023 A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)
Phase 1/2Terminated 30 Dec 2025 A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)
Phase 1Completed 28 Jul 2021 To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects
Phase 1Completed 17 Mar 2023 A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms
Phase 1Completed 29 Jan 2024 A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets
Phase 1Completed 8 Apr 2024 A Clinical Trial of Mass Balance of [14C] TQ05105 in Healthy Chinese Subjects
Phase 1Completed 17 Mar 2025 To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects
Phase 1Terminated 12 Aug 2025 TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Rovadicitinib

Following is part of Solo: you see every change to Rovadicitinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in